Biocon’s subsidiary -- Biocon Biologics India and Mylan N.V. have launched Semglee (insulin glargine injection) in vial and pre-filled pen presentations in the U.S., approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not recommended for the treatment of diabetic ketoacidosis. Semglee, which received final approval from the U.S. Food and Drug Administration (USFDA), has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
